These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
277 related articles for article (PubMed ID: 33804441)
21. Addition of the C-terminus of CD6 to a chimeric antigen receptor enhances cytotoxicity and does not compromise expression. Breuning J; Philip B; Brown MH Immunology; 2019 Feb; 156(2):130-135. PubMed ID: 30300924 [TBL] [Abstract][Full Text] [Related]
22. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains. Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568 [TBL] [Abstract][Full Text] [Related]
23. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2 Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641 [No Abstract] [Full Text] [Related]
24. T Cells Expressing NKG2D CAR with a DAP12 Signaling Domain Stimulate Lower Cytokine Production While Effective in Tumor Eradication. Ng YY; Tay JCK; Li Z; Wang J; Zhu J; Wang S Mol Ther; 2021 Jan; 29(1):75-85. PubMed ID: 32956627 [TBL] [Abstract][Full Text] [Related]
25. CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack. Chmielewski M; Hombach AA; Abken H Gene Ther; 2011 Jan; 18(1):62-72. PubMed ID: 20944680 [TBL] [Abstract][Full Text] [Related]
26. The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity. Helsen CW; Hammill JA; Lau VWC; Mwawasi KA; Afsahi A; Bezverbnaya K; Newhook L; Hayes DL; Aarts C; Bojovic B; Denisova GF; Kwiecien JM; Brain I; Derocher H; Milne K; Nelson BH; Bramson JL Nat Commun; 2018 Aug; 9(1):3049. PubMed ID: 30076299 [TBL] [Abstract][Full Text] [Related]
27. Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB. Li S; Zhang J; Wang M; Fu G; Li Y; Pei L; Xiong Z; Qin D; Zhang R; Tian X; Wei Z; Chen R; Chen X; Wan J; Chen J; Wei X; Xu Y; Zhang P; Wang P; Peng X; Yang S; Shen J; Yang Z; Chen J; Qian C Br J Haematol; 2018 May; 181(3):360-371. PubMed ID: 29637550 [TBL] [Abstract][Full Text] [Related]
28. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol. Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096 [TBL] [Abstract][Full Text] [Related]
29. Distinct functions of CAR-T cells possessing a dectin-1 intracellular signaling domain. Liang X; Huang Y; Li D; Yang X; Jiang L; Zhou W; Su J; Chen N; Wang W Gene Ther; 2023 May; 30(5):411-420. PubMed ID: 33953316 [TBL] [Abstract][Full Text] [Related]
30. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE). George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862 [TBL] [Abstract][Full Text] [Related]
31. Engineering γδT cells limits tonic signaling associated with chimeric antigen receptors. Fisher J; Sharma R; Don DW; Barisa M; Hurtado MO; Abramowski P; Porter L; Day W; Borea R; Inglott S; Anderson J; Pe'er D Sci Signal; 2019 Sep; 12(598):. PubMed ID: 31506382 [TBL] [Abstract][Full Text] [Related]
35. Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity. Torres Chavez A; McKenna MK; Canestrari E; Dann CT; Ramos CA; Lulla P; Leen AM; Vera JF; Watanabe N J Immunother Cancer; 2019 Nov; 7(1):330. PubMed ID: 31779709 [TBL] [Abstract][Full Text] [Related]
36. Generation of antitumor chimeric antigen receptors incorporating T cell signaling motifs. Balagopalan L; Moreno T; Qin H; Angeles BC; Kondo T; Yi J; McIntire KM; Alvinez N; Pallikkuth S; Lee ME; Yamane H; Tran AD; Youkharibache P; Cachau RE; Taylor N; Samelson LE Sci Signal; 2024 Jul; 17(846):eadp8569. PubMed ID: 39042728 [TBL] [Abstract][Full Text] [Related]
37. The making and function of CAR cells. Zabel M; Tauber PA; Pickl WF Immunol Lett; 2019 Aug; 212():53-69. PubMed ID: 31181279 [TBL] [Abstract][Full Text] [Related]
38. Evaluation of a Fully Human, Hepatitis B Virus-Specific Chimeric Antigen Receptor in an Immunocompetent Mouse Model. Festag MM; Festag J; Fräßle SP; Asen T; Sacherl J; Schreiber S; Mück-Häusl MA; Busch DH; Wisskirchen K; Protzer U Mol Ther; 2019 May; 27(5):947-959. PubMed ID: 30852138 [TBL] [Abstract][Full Text] [Related]
39. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy. Ma Q; Gomes EM; Lo AS; Junghans RP Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378 [TBL] [Abstract][Full Text] [Related]
40. CD28 Costimulatory Domain-Targeted Mutations Enhance Chimeric Antigen Receptor T-cell Function. Boucher JC; Li G; Kotani H; Cabral ML; Morrissey D; Lee SB; Spitler K; Beatty NJ; Cervantes EV; Shrestha B; Yu B; Kazi A; Wang X; Sebti SM; Davila ML Cancer Immunol Res; 2021 Jan; 9(1):62-74. PubMed ID: 33188139 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]